ProShare Advisors LLC Sells 574 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

ProShare Advisors LLC reduced its stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 7.7% during the 2nd quarter, Holdings Channel reports. The firm owned 6,865 shares of the specialty pharmaceutical company’s stock after selling 574 shares during the period. ProShare Advisors LLC’s holdings in Jazz Pharmaceuticals were worth $733,000 at the end of the most recent quarter.

A number of other institutional investors have also made changes to their positions in the stock. Kovack Advisors Inc. boosted its holdings in Jazz Pharmaceuticals by 88.8% during the first quarter. Kovack Advisors Inc. now owns 56,599 shares of the specialty pharmaceutical company’s stock worth $6,816,000 after buying an additional 26,628 shares during the last quarter. John G Ullman & Associates Inc. bought a new position in Jazz Pharmaceuticals during the 1st quarter worth approximately $3,631,000. Swedbank AB acquired a new position in Jazz Pharmaceuticals during the second quarter valued at approximately $106,936,000. Vanguard Group Inc. increased its stake in Jazz Pharmaceuticals by 1.3% in the first quarter. Vanguard Group Inc. now owns 6,448,689 shares of the specialty pharmaceutical company’s stock valued at $776,551,000 after purchasing an additional 84,941 shares in the last quarter. Finally, APG Asset Management US Inc. acquired a new stake in Jazz Pharmaceuticals in the fourth quarter worth $1,389,000. 89.14% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the stock. JPMorgan Chase & Co. boosted their price target on shares of Jazz Pharmaceuticals from $190.00 to $202.00 and gave the company an “overweight” rating in a report on Monday, August 19th. Wells Fargo & Company decreased their target price on Jazz Pharmaceuticals from $140.00 to $120.00 and set an “equal weight” rating for the company in a research note on Thursday, August 1st. StockNews.com raised Jazz Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Thursday, August 1st. Piper Sandler decreased their price objective on Jazz Pharmaceuticals from $188.00 to $166.00 and set an “overweight” rating for the company in a research report on Thursday, August 1st. Finally, Needham & Company LLC reissued a “buy” rating and set a $205.00 target price on shares of Jazz Pharmaceuticals in a research note on Tuesday, September 10th. Three equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $173.07.

Insiders Place Their Bets

In other news, SVP Mary Elizabeth Henderson sold 1,410 shares of Jazz Pharmaceuticals stock in a transaction dated Friday, September 6th. The shares were sold at an average price of $108.30, for a total value of $152,703.00. Following the completion of the transaction, the senior vice president now owns 14,531 shares of the company’s stock, valued at approximately $1,573,707.30. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 4.20% of the company’s stock.

Jazz Pharmaceuticals Trading Up 0.7 %

Shares of NASDAQ:JAZZ opened at $110.93 on Friday. The stock has a market capitalization of $7.00 billion, a PE ratio of 22.87, a price-to-earnings-growth ratio of 1.36 and a beta of 0.57. The company’s 50-day moving average price is $111.02 and its two-hundred day moving average price is $110.82. The company has a debt-to-equity ratio of 1.36, a current ratio of 2.37 and a quick ratio of 2.02. Jazz Pharmaceuticals plc has a one year low of $99.06 and a one year high of $137.38.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its quarterly earnings results on Wednesday, July 31st. The specialty pharmaceutical company reported $4.67 earnings per share for the quarter, beating analysts’ consensus estimates of $3.80 by $0.87. Jazz Pharmaceuticals had a return on equity of 28.65% and a net margin of 10.10%. The firm had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $1 billion. On average, equities analysts forecast that Jazz Pharmaceuticals plc will post 16.03 EPS for the current fiscal year.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.